secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001558370-23-013487
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Q2 net loss widens to $29.6M; zunsemetinib RA data expected Q4 2023
---------------------------------------------------------------------------

- Net loss $29.6M vs $20.5M YoY; revenue $1.9M vs $1.5M, driven by licensing royalties.
- Cash $210.8M, sufficient through 2025; includes $26.7M from ATM share sale in April 2023.
- Zunsemetinib Phase 2b RA trial enrollment completed; topline data expected Q4 2023.
- ATI-2138 Phase 1 MAD completed in healthy volunteers; data expected September 2023.
- G&A expenses $8.3M include bad debt from EPI Health bankruptcy filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023013487/0001558370-23-013487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023013487/acrs-20230807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-013487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer